PSFG
LGND icon

Park Square Financial Group’s Ligand Pharmaceuticals LGND Stock Holding History

Park Square Financial Group’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-20
Closed -$2.27K – 661
2025
Q2 		$2.27K Buy
+20
New +$2.14K ﹤0.01% 869
2025
Q1 		– Sell
-20
Closed -$2.14K – 1012
2024
Q4 		$2.14K Buy
+20
New +$2.26K ﹤0.01% 829

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Park Square Financial Group's LGND Position: Q3 2025 in Review

Park Square Financial Group sold out of Ligand Pharmaceuticals (LGND) in Q3 2025, closing a stake of 20 shares — an estimated $2.27K sold.

Park Square Financial Group first reported a position in LGND in Q4 2024 and held it in 2 quarters. The position peaked at $2.27K in Q2 2025. 314 funds tracked by Wall St. Rank hold LGND as of Q3 2025.

  • Park Square Financial Group reported no remaining Ligand Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Park Square Financial Group sold 20 Ligand Pharmaceuticals shares in Q3 2025, an estimated $2.27K.
  • Park Square Financial Group first reported a position in Ligand Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Park Square Financial Group's Ligand Pharmaceuticals position peaked at $2.27K in Q2 2025.
  • 314 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2025.

Based on Park Square Financial Group's 13F filing for Q3 2025, filed 12 Nov 2025.